Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Astrid Lièvre

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2118-717X; OpenAlex author ID A5074346281. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 9

  1. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  2. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  3. Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial. Co-author DOI 10.6004/jnccn.2023.7065↗
  4. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
  5. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
  6. FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Co-author DOI 10.1177/17588359211029825↗
  7. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Co-author DOI 10.1634/theoncologist.2020-0577↗
  8. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  9. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Last author DOI 10.1016/j.dld.2017.02.007↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julien Edeline · 6 shared papers, 2017–2022 · strength 0.62
  2. Anthony Turpin · 3 shared papers, 2020–2026 · strength 0.42
  3. Olivier Bouché · 2 shared papers, 2023–2026 · strength 0.34
  4. Cindy Neuzillet · 3 shared papers, 2019–2023 · strength 0.31
  5. Sonia Zaibet · 2 shared papers, 2022 · strength 0.26
  6. Édouard Auclin · 2 shared papers, 2022 · strength 0.26
  7. Matthieu Sarabi · 2 shared papers, 2022 · strength 0.26
  8. Dominique Béchade · 2 shared papers, 2022 · strength 0.26
  9. Julien Taı̈eb · 2 shared papers, 2022 · strength 0.26
  10. Simon Pernot · 2 shared papers, 2022 · strength 0.26
  11. Marine Gilabert · 2 shared papers, 2022 · strength 0.26
  12. David Tougeron · 2 shared papers, 2022 · strength 0.26
  13. Pascal R. Hammel · 2 shared papers, 2020–2023 · strength 0.25
  14. Mircea Chirica · 1 shared paper, 2026 · strength 0.20
  15. Christelle d’Engremont · 1 shared paper, 2026 · strength 0.20
  16. Gaël S. Roth · 1 shared paper, 2026 · strength 0.20
  17. Pauline Parent · 1 shared paper, 2026 · strength 0.20
  18. Jean‐Frédéric Blanc · 1 shared paper, 2026 · strength 0.20
  19. Jerome F. Cros · 1 shared paper, 2026 · strength 0.20
  20. Jean‐Yves Scoazec · 1 shared paper, 2026 · strength 0.20
  21. Patrick Mehlen · 1 shared paper, 2026 · strength 0.20
  22. Camille Evrard · 1 shared paper, 2026 · strength 0.20
  23. Jean‐Baptiste Bachet · 1 shared paper, 2026 · strength 0.20
  24. Nicolas Williet · 1 shared paper, 2026 · strength 0.20
  25. Déwi Vernerey · 2 shared papers, 2019–2020 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.